Monte Rosa Therapeutics
GLUE
66 hedge funds and large institutions have $314M invested in Monte Rosa Therapeutics in 2022 Q4 according to their latest regulatory filings, with 6 funds opening new positions, 26 increasing their positions, 17 reducing their positions, and 10 closing their positions.
4,345% more call options, than puts
Call options by funds: $489K | Put options by funds: $11K
53% more repeat investments, than reductions
Existing positions increased: 26 | Existing positions reduced: 17
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
0.99% less ownership
Funds ownership: 86.18% → 85.19% (-0.99%)
4% less capital invested
Capital invested by funds: $328M → $314M (-$14.1M)
6% less funds holding
Funds holding: 70 → 66 (-4)
40% less first-time investments, than exits
New positions opened: 6 | Existing positions closed: 10
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
ACA
Avoro Capital Advisors
New York
|
+$8.01M |
| 2 |
Millennium Management
New York
|
+$3.06M |
| 3 |
BlackRock
New York
|
+$1.07M |
| 4 |
Geode Capital Management
Boston,
Massachusetts
|
+$277K |
| 5 |
State Street
Boston,
Massachusetts
|
+$273K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
CAM
Cormorant Asset Management
Boston,
Massachusetts
|
-$833K |
| 2 |
O
OrbiMed
New York
|
-$750K |
| 3 |
UOC
UBS O'Connor
Chicago,
Illinois
|
-$748K |
| 4 |
HF
HRT Financial
New York
|
-$700K |
| 5 |
T. Rowe Price Associates
Baltimore,
Maryland
|
-$666K |
GLUE Hedge Fund Activity: Q4 2022 in Review
66 of the 6,221 institutional investors tracked by Wall St. Rank reported a position in Monte Rosa Therapeutics (GLUE) for Q4 2022, worth a combined $314M — down 4.3% from $328M a quarter earlier.
Sellers outnumbered buyers: 10 funds closed out of GLUE and 6 opened new positions — a net loss of 4 holders — while 17 trimmed existing stakes and 26 added.
The largest buyer was Avoro Capital Advisors, adding an estimated $8.01M. The largest seller was Cormorant Asset Management, cutting an estimated $833K.
- 66 institutional investors held Monte Rosa Therapeutics (GLUE) as of Q4 2022, down from 70 in Q3 2022.
- Funds reported $314M of Monte Rosa Therapeutics stock for Q4 2022, down 4.3% quarter-over-quarter.
- 6 funds opened new Monte Rosa Therapeutics positions in Q4 2022 and 10 closed out, a net change of -4 holders.
- The largest Monte Rosa Therapeutics buyer in Q4 2022 was Avoro Capital Advisors, an estimated $8.01M added.
- The largest Monte Rosa Therapeutics seller in Q4 2022 was Cormorant Asset Management, an estimated $833K sold.
Based on aggregated 13F filings for Q4 2022.